NCT03648814Recruiting
Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT
Efficacy and Safety of Intracameral Versus Intravitreal Bevacizumab Injection as an Adjunctive Therapy Before Trabeculectomy With Mitomycin-C in Neovascular Glaucoma: A Prospective Randomized Trial
Source: ClinicalTrials.gov · Last updated 21 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 24 Aug 2018
- Start date
- 1 Aug 2018
- Primary completion date
- 1 Jul 2026
- Lead sponsor
- Prince of Songkla University
- Diseases
- Glaucoma
- NCT number
- NCT03648814
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 1 Aug 2018 to the primary completion date, 1 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of bevacizumab or fluorescence dye allergy.
- Active infectious ocular disease including endophthalmitis and corneal ulcer
- History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension
Lab values
- Cannot obtain endothelial cell count.
Other
- One eye patient
- Patients having severe corneal edema or total hyphema obscure NVI or NVA view.
- Has or planning to be pregnant or breastfeeding
Who the study is looking for
- Diagnosis of neovascular glaucoma
- The patients having IOP \> 21 mmHg, having the indication for trabeculectomy
- The patients' age of at least 18-year-old
- The patients having visual potential at least hand motion.
- Present of NVI or NVA.
- Willing and able to provide informed consent to participate in the study
- Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University Coordinator of this site? Confirm its status | Hat Yai | Thailand | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.